ADVFN - Advanced Financial Network.
HOME» NASDAQ » G » GILD Stock Price » GILD Stock News

Gilead Sciences Share News

 Gilead Sciences (mm) Stock Price
GILD Stock Price
 Gilead Sciences (mm) Stock Chart
GILD Stock Chart
 Gilead Sciences (mm) Stock News
GILD Stock News
 Gilead Sciences (mm) Company Information
GILD Company Information
 Gilead Sciences (mm) Stock Trades
GILD Stock Trades

Gilead: Majority Of Certain Hep C Genotype 1 Patients Saw Viral Relapse

DOW JONES NEWSWIRES Gilead Sciences Inc. (GILD) said the majority of certain hepatitis C genotype 1 patients it treated with its GS-7977 drug plus ribavirin had viral relapse within four weeks of completing 12 weeks of treatment, potentially putting into question the efficacy of the drug in some patients. Shares were down 8.8% premarket at $50. As of Thursday's close, the stock has risen 34% since the start of 2012. The biopharmaceutical last month completed its purchase of Pharmasset Inc. for more than $11 billion, in a deal expected to accelerate its hepatitis C drug pipeline. It said earlier this month that its GS-7977 drug--which it acquired in the deal--along with the older drug ribavirin, made hepatitis C undetectable after four weeks of treatment in all 10 patients with genotypes 2 and 3 treated. The trial was also the first to successfully eliminate interferon from the drug treatment. Interferon is a highly toxic, older hepatitis C drug with major side effects, and market watchers are keenly focused on drug developers finding ways to strip out that treatment from future hepatitis C regimens. But, among eight genotype 1 patients treated, six experienced viral relapse. Two patients didn't, but they have only reached the two-week post-treatment time point. Those patients had a prior "null" response to an interferon-containing regimen. "These data answer an important question about the use of GS-7977 and ribavirin for the treatment of genotype 1 null responder patients, suggesting that additional direct acting antivirals may be necessary to effectively treat this patient population," said Chief Scientific Officer Norbert Bischofberger. "We will continue to explore a number of therapeutic approaches to address this significant unmet medical need, including combinations with other oral antivirals." Results from ongoing studies, including those involving genotype 1 treatment-native patients, will be released in the coming months. Gilead earlier this month said its fourth-quarter earnings rose as the company's product sales continued to rise and it no longer booked deep reductions in royalties. -By Ben Fox Rubin, Dow Jones Newswires; 212-416-3108;

Stock News for Gilead Sciences (GILD)
04/28/201513:04:0210 Most Profitable Businesses in Biotech
04/28/201512:07:45Notice of Exempt Solicitation. Definitive Material. (px14a6g)
04/28/201510:59:12Bristol-Myers Squibb Crushes First-Quarter Earnings: Here's Why
04/28/201509:58:39Aetna Boosts Profit Outlook -- Update
04/28/201507:30:41Aetna Boosts Profit Outlook
04/28/201507:17:023 Things to Watch with Gilead Sciences Inc.'s Q1 Earnings
04/28/201507:07:51Aetna Boosts Profit Outlook
04/27/201515:19:29Needham & Company LLC Analysts Give Gilead Sciences a $120.00...
04/27/201513:03:02Biotech Bubble Bursting? 3 Stocks I Want to Buy
04/27/201510:10:09Bristol-Myers Hepatitis C Therapy With Sovaldi Meets Study Goals
04/27/201509:46:17Bristol-Myers Hepatitis C Therapy With Sovaldi Meets Study Goals
04/27/201504:58:43Gilead Sciences Now Covered by Oppenheimer (GILD)
04/26/201513:02:02Can You Guess Which State Won't Pay for Hepatitis C Drugs?
04/26/201509:17:43MARKET SNAPSHOT: Apple, Energy, Health Care Earnings To Dominate...
04/26/201508:01:02Why Healthcare is the Best Sector For Your Money
04/26/201505:47:00Gilead gibt Ergebnisse aus Studien zu auf Sofosbuvir basierenden...
04/25/201522:14:00Gilead annonce les résultats d'études évaluant des traitements à...
04/25/201522:14:00Gilead comunica i risultati derivati dagli studi condotti ai...
04/25/201501:00:00Gilead Announces Results From Studies Evaluating Sofosbuvir-Based...
04/24/201515:46:50Gilead Sciences Stock Rating Reaffirmed by Morgan Stanley (GILD)

Gilead Sciences and other NASDAQ stock quotes are delayed by at least 20 minutes.
All other stock price and quote data is delayed by at least 15 minutes unless otherwise stated. By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Contact Us | Copyright 1999-2007 ADVFN PLC. | Privacy Policy | Investment Warning | Data accreditations | Investor Relations